Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 1, 2012, Pages 91-95

  Lee, Young In ^a   Lim, Young Suk ^a   Park, Hye Soon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adenomatous polyps; Association; Colorectal cancer; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADENOMATOUS POLYP; ADULT; AGE; AGED; ARTICLE; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH KOREA;

EID: 84155178375     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06816.x     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2009. CA Cancer J. Clin. 2009; 59: 225-49.
2. Wolf I, Sadetzki S, Kanety H etal. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006; 106: 966-73.
3. Korea National Statistical Office. 2008 Report of Statistics in Mortality in Korean. 2009.
4. Leslie A, Carey FA, Pratt NR etal. The colorectal adenoma-carcinoma sequence. Br. J. Surg. 2002; 89: 845-60.
5. Ahmed RL, Schmitz KH, Anderson KE etal. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107: 28-36.
6. Limburg PJ, Anderson KE, Johnson TW etal. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 133-7.
7. Murphy TK, Calle EE, Rodriguez C etal. Body mass index and colon cancer mortality in a large prospective study. Am. J. Epidemiol. 2000; 152: 847-54.
8. Schiel R, Muller UA, Braun A etal. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur. J. Med. Res. 2005; 10: 339-44.
9. Kim JH, Lim YJ, Kim YH etal. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol. Biomarkers Prev. 2007; 16: 1543-6.
10. Lee GE, Park HS, Yun KE etal. Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity 2008; 16: 1434-9.
11. Colangelo LA, Gapstur SM, Gann PH etal. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 385-91.
12. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am. J. Clin. Nutr. 2007; 86: s836-42.
13. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr. 2001; 131 (Suppl.): s3109-20.
14. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes. Metab. 2008; 34 (Pt 2): 634-7.
15. Angelico F, Del Ben M, Conti R etal. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2005; 90: 1578-82.
16. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 722-8.
17. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
18. American Gastroenterological Association. American Gastroenterological Association medical position statement. nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-4.
19. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40 (Suppl. 1): s5-10.
20. Komeda T. Obesity and NASH in Japan. Hepatol. Res. 2005; 33: 83-6.
21. Seo SH, Lee HW, Park HW etal. Prevalence and associated factors of nonalcoholic fatty liver disease in the health screen examinees. Korean J. Med. 2006; 70: 26-32.
22. Jarrar MH, Baranova A, Collantes R etal. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008; 27: 412-21.
23. Targher G, Bertolini L, Scala L etal. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet. Med. 2005; 22: 1354-8.
24. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J. Clin Ultrasound. 1996; 24: 25-9.
25. Palmentieri B, de Sio I, La Mura V etal. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig. Liver Dis. 2006; 38: 485-9.
26. Sorensen HT, Mellemkjaer L, Jepsen P etal. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J. Clin. Gastroenterol. 2003; 36: 356-9.
27. Hwang ST, Cho YK, Park JH etal. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J. Gastroenterol. Hepatol. 2010; 25: 562-7.
28. Morita T, Tabata S, Mineshita M etal. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac. J. Cancer Prev. 2005; 6: 485-9.
29. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur. J. Cancer 2008; 44: 293-7.
30. Keku TO, Lund PK, Galanko J etal. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 2076-81.
31. Bellentani S, Saccoccio G, Masutti F etal. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000; 132: 112-17.
32. Nomura H, Kashiwagi S, Hayashi J etal. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 1988; 27: 142-9.
33. Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1-10.
34. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin. Liver Dis. 2007; 11: 37-54.
35. Graif M, Yanuka M, Baraz M etal. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest. Radiol. 2000; 35: 319-24.
36. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.